Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea (original) (raw)

Abstract

Our purpose was to assess the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with AHF.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (36)

  1. support from Roche, Biosite, and Bayer, and is a consultant to Biosite. Dr. Mueller has received research grants from the Swiss National Sci- ence Foundation, the Swiss Heart Foundation, the Novartis Foundation, the Krokus Foundation, Abbott, Biosite, BRAHMS, Roche, and the University of Basel. Dr. Pea- cock is on the Scientific Advisory Board of Abbott, Beckman-Coulter, Biosite, Inverness, Ortho Clinical Diag- nostics, and Response Biomedical, and has received research grants from Abbott, Biosite, and Inverness. Dr. Ponikowski has received honoraria for serving as a consultant for Vifor and Athera, and as a speaker for Merck-Serono, Pfizer, and Sanofi-Aventis. Dr. Richards is on the Scientific Advisory Board of Inverness Medical, and has received travel support, honoraria, and research grants from Roche Diagnostics and Inverness Medical (Biosite). Dr. Filippatos has received research support from Biosite, BRAHMS, and Roche. Dr. Di Somma is a consultant to Biosite. Dr. Ng is a consultant for Inverness Medical Innovations and BRAHMS AG. Dr. Daniels has received research support from Biosite Inc. and Roche Diagnostics. Dr. Neath is a consultant to BRAHMS USA. Dr. Christensen is a consultant for Sie- mens, BG-Medicine, Critical Care Diagnostics, Inverness Medical, and Abbott Diagnostics, and has received research support from Siemens, BG-Medicine, BRAHMS, Roche, Inverness Medical, and Nanosphere. Dr. McCord has REFERENCES
  2. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669 -74.
  3. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
  4. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunore- active B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008; 52:534 -40.
  5. Farmakis D, Filippatos G, Tubaro M, et al. Natriuretic peptides in acute coronary syndromes: prognostic value and clinical implications. Congest Heart Fail 2008;14 Suppl 1:25-9.
  6. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000;66:855-72.
  7. Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370 -6.
  8. Jougasaki M, Wei CM, McKinley LJ, Burnett JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92:286 -9.
  9. Nishikimi T, Saito Y, Kitamura KI, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995;26:1424 -31.
  10. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369 -72.
  11. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunolumino- metric assay. Clin Chem 2005;51:1823-9.
  12. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunolumi- nometric assay for the midregion of pro-atrial natriuretic Peptide in human plasma. Clin Chem 2004;50:234 -6.
  13. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:725-8.
  14. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intens Care Med 1995;21:24 -31.
  15. Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990;89:713-21.
  16. Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857-64.
  17. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-32.
  18. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B- type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-80.
  19. Gegenhuber A, Struck J, Poelz W, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006;52:827-31.
  20. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42-9.
  21. DeLong ER, DeLong DM, Coarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
  22. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
  23. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation 2002;106:416.
  24. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247-52.
  25. Möckel M, Müller R, Vollert JO, et al. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin Chem 2005;51:1624 -31.
  26. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
  27. European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM), Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008;10:933-89.
  28. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure on the European Society of Cardiology. Eur Heart J 2005;26:384 -416.
  29. ACC/AHA collaborate on guidelines for the evaluation and manage- ment of heart failure. Am Fam Physician 1996;53:2196 -8.
  30. Maisel A, Mueller C, Adams K Jr., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824 -39.
  31. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heteroge- neity has a major impact on the measurement of circulating N-terminal fragments of A-and B-type natriuretic peptides. Clin Chem 2004;50:1576 -88.
  32. Key Words: pro-hormone y markers y acute dyspnea y BACH. doi:10.1016/j.jacc.2010.02.025 2010;55;2062-2076
  33. J. Am. Coll. Cardiol. Stefan D. Anker
  34. Hartmann, Stephan von Haehling, Andreas Bergmann, Nils G. Morgenthaler, and Potocki, James McCord, Garret Terracciano, Dimitrios Kremastinos, Oliver
  35. Anand, Leong Ng, Lori B. Daniels, Sean-Xavier Neath, Robert Christenson, Mihael Mark Richards, Paul Clopton, Gerasimos S. Filippatos, Salvatore Di Somma, Inder
  36. Landsberg, Piotr Ponikowski, Martin Mockel, Christopher Hogan, Alan H.B. Wu, Alan Maisel, Christian Mueller, Richard Nowak, W. Frank Peacock, Judd W. Dyspnea: Results From the BACH (Biomarkers in Acute Heart Failure) Trial Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute This information is current as of September 27, 2011